Loading...
Temporal Aspects of the Action of ASA404 (Vadimezan; DMXAA)
ASA404, a flavonoid tumor-vascular disrupting agent (Tumor-VDA), is in clinical trial for the treatment of non-small cell lung cancer. Its action differs from both that of the tubulin binding class of Tumor-VDAs and antiangiogenic agents. In mice, ASA404 induces a sequence of changes in tumor tissue...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3583340/ https://ncbi.nlm.nih.gov/pubmed/20964495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543784.2010.529128 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|